Monoclonal antibody 323A3

Drug Profile

Monoclonal antibody 323A3

Alternative Names: 323A3; Monoclonal antibody 323-A3

Latest Information Update: 18 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centocor
  • Developer Centocor; Nonindustrial source
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer

Most Recent Events

  • 18 May 2010 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
  • 18 May 2010 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
  • 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top